Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8249)	1/8/1999 3:28:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Xoma is a provider of monoclonal antibody technology to several biotechs. It seems that the GNE agreement was based on this type of expertise. The last press release mentioned "xoma's scalable manufacturing process" they have the ability for large production in place, GNE should take into account building a new facility vs taking a proven facility already at work, FDA inspected, and all that that take lots of time and resources. Outsourcing this work to xoma is cheaper, payments vs rayalties it looks like Xoma is in good position here. Maybe GNE scientists do have the ability to generate the ideas and patents in the field, and some manufacturing ability for limited research in the monoclonal antibody area. GNE big facilities are in recombinant DNA expresion for protein production in yeast, like the process for their growth hormone, TPA (competitor of Bpi in the future, or combination ?) and Pulmozyne (the best for cystic fibrosi patients in decades, combination with BPI?,) they already are marketing to the Cystic fibrosis patients fully. Pulmozyme is recombinant dornase (DNAse)alfa to get rid of heavy mucous plugs from the lungs of the cystic fibrosis sufferer, but it does not get rid of bacteria, Bpi will. Another recent product in the field coming is TOBI (a version of the tobramycin antibiotic).

To: aknahow who wrote (8249)	1/8/1999 4:30:00 PM
From: LLCF	Read Replies (1) \| Respond to of 17367

<What is clear, is that if hu1124 eventually becomes a commercial product XOMA at its' option gets a cash payment(s) or profit sharing. The term royalties was not used, so I must assume they really meant profit sharing. But since the terms of the two options were not disclosed I have no idea of what either option will mean for XOMA.> Thank-you very much... I was not aware of this. I am relatively new to XOMA, it is recommended by CTSL and MTSL as you know. This fall i decided that there was so much potential in biotech (all the articles that have been saying the next 5 years should see tons of approvals, blah blah blah... you know the story) that I would briefly look into 10 or 15 of those guys picks and buy 'em... so far I'm doing better than I ever thought, but want to really follow the stories as they unfold and hold some Long term.... and take profits in some, etc. Any help is appreciated. DAK